Tin tức & Cập nhật

Combination treatment with abemaciclib and a nonsteroidal aromatase inhibitor (NSAI) as initial therapy, compared with NSAI alone, helps extend survival in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer, results of the MONARCH 3 study have shown.

Treatment with the combination of regorafenib, nivolumab, and short-course radiotherapy (SCRT) in the neoadjuvant setting has induced response in stage II-III rectal adenocarcinoma in the phase II REGINA trial, meeting the predefined statistical criteria.

A recent study has noted the excellent specificity and negative predictive value of FIB-4 and nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) in diagnosing advanced fibrosis (AF, bridging fibrosis or cirrhosis) among people living with HIV (PWH).

Patients with high-risk locally advanced cervical cancer in East Asia get progression-free survival (PFS) boost with pembrolizumab plus concurrent chemoradiotherapy (CCRT), similar to those observed in the overall population of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.